Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure

Roberto Latini, Serge Masson, Inder S. Anand, Emil Missov, Marjorie Carlson, Tarcisio Vago, Laura Angelici, Simona Barlera, Giovanni Parrinello, Aldo P. Maggioni, Gianni Tognoni, Jay N. Cohn

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND - Circulating cardiac troponin T, a marker of cardiomyocyte injury, predicts adverse outcome in patients with heart failure (HF) but is detectable in only a small fraction of those with chronic stable HF. We assessed the prognostic value of circulating cardiac troponin T in patients with stable chronic HF with a traditional (cTnT) and a new precommercial highly sensitive assay (hsTnT). METHODS AND RESULTS - Plasma troponin T was measured in 4053 patients with chronic HF enrolled in the Valsartan Heart Failure Trial (Val-HeFT). Troponin T was detectable in 10.4% of the population with the cTnT assay (detection limit ≤0.01 ng/mL) compared with 92.0% with the new hsTnT assay (≤0.001 ng/mL). Patients with cTnT elevation or with hsTnT above the median (0.012 ng/mL) had more severe HF and worse outcome. In Cox proportional hazards models adjusting for clinical risk factors, cTnT was associated with death (780 events; hazard ratio=2.08; 95% confidence interval, 1.72 to 2.52; P

Original languageEnglish
Pages (from-to)1242-1249
Number of pages8
JournalCirculation
Volume116
Issue number11
DOIs
Publication statusPublished - Sep 2007

Keywords

  • Heart failure
  • Natriuretic peptides
  • Prognosis
  • Troponin

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure'. Together they form a unique fingerprint.

Cite this